NUVB · Nuvation Bio Inc.
$4.57
-2.77% last session
End-of-day data · close of 2026-10-23
Market cap
$2B
Enterprise value
$1B
Trailing P/E
—
Forward P/E
-304.7
Dividend yield
0.0%
Beta
1.62
Avg volume
5M
Employees
0K
Daily Change %
-2.77%
5 Days Change
5.62%
10 Days Change
-0.42%
30 Days Change
-17.69%
60 Days Change
-30.47%
Month to Day Change
-15.47%
Year to Day Change
-47.54%
Analyst Outlook
Analyst estimates change daily — follow the shifts on the Estimate Trends page.
Technical Analysis
Analyst sentiment over time — NUVB
Rec Mean (blue, left — higher = more bullish) vs. price targets (right).
Investment Bank Ratings as of 2026-09-30
Latest call per bank · past 12 months
Citigroup
Buy$12.00
+162.6% vs priceJP Morgan
Overweight$13.00
+184.5% vs priceRBC Capital
Outperform$20.00
+337.6% vs priceUBS
Neutral$7.00
+53.2% vs priceRecent rating actions
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-09-30 | Citigroup | Initiates | Buy | $0.00 → $12.00 |
| 2026-09-16 | Citizens | Reiterates | Market Outperform | $10.00 |
| 2026-09-16 | Wedbush | Reiterates | Outperform | $11.00 |
| 2026-08-21 | Cantor Fitzgerald | Initiates | Overweight | $0.00 |
| 2026-08-18 | JP Morgan | Initiates | Overweight | $0.00 → $13.00 |
| 2026-08-07 | RBC Capital | Maintains | Outperform | $19.00 → $20.00 |
| 2026-07-27 | HC Wainwright & Co. | Maintains | Buy | $17.00 → $21.00 |
| 2026-07-23 | Wedbush | Reiterates | Outperform | $11.00 |
Ratings and price targets are the published opinions of the issuing banks, compiled from Yahoo Finance rating actions — not investment advice.
Signal Summary as of 2026-10-23
- neutral: RSI (14): RSI is 34 — neutral momentum, neither overbought nor oversold.
- bearish: Price vs 50-day MA: Trading 21.9% below the 50-day MA ($5.85).
- bearish: Price vs 200-day MA: Trading 16.3% below the 200-day MA ($5.46).
- bullish: MA cross: The 50-day MA sits above the 200-day MA (golden-cross regime) — the longer-term trend points up.
- bullish: MACD (12,26,9): MACD histogram is positive (+0.02) — short-term momentum is improving.
- neutral: 52-week range: Price sits between the 52-week low ($4.05) and high ($9.54).
NUVB Price Chart
Loading chart for NUVB…
Fundamentals
About Nuvation Bio Inc.
Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on developing product candidates for cancer treatment. The company's lead product candidate is IBTROZI (taletrectinib), a ROS1 inhibitor for the treatment of patients with ROS1+ non-small cell lung cancer. It is also developing Safusidenib, an inhibitor of mutant isocitrate dehydrogenase 1 in phase 3 clinical trials for the maintenance treatment of high-risk or high-grade IDH1-mutant astrocytoma with safusidenib against placebo. The company was founded in 2018 and is headquartered in New York, New York.
More in Biotechnology
VRTX
Vertex Pharmaceuticals Incorpor
$133B 18.1% YTD
REGN
Regeneron Pharmaceuticals, Inc.
$83B 6.5% YTD
MRNA
Moderna, Inc.
$80B 587.1% YTD
ARGX
argenx SE
$55B 4.1% YTD
ONC
BeOne Medicines Ltd.
$43B 25.8% YTD
RVMD
Revolution Medicines, Inc.
$40B 135.6% YTD
RPRX
Royalty Pharma plc
$37B 67.3% YTD
ALNY
Alnylam Pharmaceuticals, Inc.
$30B -42.8% YTD
Data is sourced from end-of-day snapshots and refreshed daily before the US market open — nothing on this page is real-time. Figures can contain vendor errors. This page is for information only and is not investment advice.